— Know what they know.
Not Investment Advice
Also trades as: DRMAW (NASDAQ) · $vol 0M

DRMA NASDAQ

Dermata Therapeutics, Inc.
1W: -4.8% 1M: -11.9% 3M: -7.8% YTD: -45.9% 1Y: +49.2% 3Y: -97.0%
$1.25
+0.07 (+5.93%)
After Hours: $1.23 (-0.02, -1.60%)
Weekly Expected Move ±7.2%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 27 · $804237 mcap · 498526 float · 290.82% daily turnover · Short 39% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$0.8M
52W Range1.1-8.5
Volume42,461
Avg Volume1,449,829
Beta0.67
Dividend
Analyst Ratings
1 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOGerald T. Proehl
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2021-08-13
3525 Del Mar Heights Road
San Diego, CA 92130
US
858 800 2543
About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Recent Insider Trades

NameTypeSharesPriceDate
Bedoya-Toro Munera M P-Purchase 1,000 $1.27 2026-02-17
PROEHL GERALD T A-Award 37,500 $2.18 2026-01-02
HALE DAVID F A-Award 2,500 $2.18 2026-01-02
WIERENGA WENDELL A-Award 2,500 $2.18 2026-01-02
Bedoya-Toro Munera M A-Award 9,000 $2.18 2026-01-02

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms